Expression of Bcl-2 protein in human primary breast carcinomas and its correlation with multifocality, histopathological types and prognosis

European Journal of Cancer Part A

Volumn 33, Issue 8, 1997, Pages 1275-1280

  Papadimitriou, C S ^a   Costopoulos, J S ^a   Christoforidou, B P ^a   Kotsianti, A J ^a   Karkavelas, G S ^a   Hytiroglou, P M ^a   Koufogiannis, D J ^a   Nenopoulou, H E ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Bcl 2 protein; Breast cancer; Breast carcinoma; Immunohistochemistry; Oncogene

Indexed keywords

GENE PRODUCT; PROTEIN BCL 2;

ADULT; ARTICLE; BREAST CARCINOMA; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CANCER; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; LYMPH NODES; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030742691     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00124-X     Document Type: Article

References (46)

1. Tsujimoto Y, Cossman J, Jaffe E, Croce E. Involvement of the Bcl-2 gene in human follicular lymphoma. Science 1985, 2728, 1440.
2. Van Slooten HJ, Clahsen PC, Dierendonck JH van, et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996, 74, 78-85.
3. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348, 334-336.
4. Pezzella F, Tse A, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the Bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990, 137, 225-232.
5. Zutter M, Hockenbery D, Silverman GA, Korsmeyer SJ. Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood 1991, 78, 1062-1068.
6. Le Brun DP, Warnke RA, Cleary ML. Expression of Bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993, 142, 743-753.
7. Lu QL, Poulsom R, Wong L, Hanby AM. BCL-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 1993, 169, 431-437.
8. Lotem J, Sachs L. Regulation of Bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and defective myeloid leukemic cells. Cell Growth Differ 1993, 4, 41-47.
9. 2+ concentrations. Arch Biochem Biophys 1989, 269, 365-370.
10. Viale G, Roncalli M, Grimelius L, et al. Prognostic value of Bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol 1995, 26, 945-950.
11. McDonnell TJ, Toncoso P, Brisbay SM, et al. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52, 6940-6944.
12. Tahara E. Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 1993, 119, 265-272.
13. Pezzella F, Turley J, Juzu I, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993, 329, 690-694.
14. Brada M. Bcl-2 gene: current relevance to clinical oncology. Eur J Cancer 1992, 28, 270-272.
15. Nathan B, Gusterson B, Jadayel D, et al. Expression of Bcl-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann Oncol 1994, 5, 409-414.
16. Egan RL. Multicentre breast carcinomas: clinical-radio-graphic-pathologic whole organ studies and 10-year survival. Cancer 1982, 49, 1123-1130.
17. Fechner RE. Histologic variants of infiltrating lobular carcinoma of breast. Hum Pathol 1979, 6, 373-378.
18. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW. Infiltrating lobular carcinoma of the breast. Histopathology 1982, 6, 149-161.
19. Bloom H, Richardson W. Histological grading and prognosis in breast cancer. Br J Cancer 1957, 9, 359-377.
20. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (3) 1994, 11(3), 167-180.
21. Bargou RC, Daniel PT, Mapara MY, et al. Expression of the Bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995, 69(6), 854-859.
22. Kernohan NM, Cox S. Regulation of apoptosis by Bcl-2 and its related proteins: immunohistochemical challenges and therapeutic implications. J Pathol 1996, 179, 1-3.
23. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virch Arch 1994, 424, 47-51.
24. Joensuu H, Pylkkanen L, Toikanen S. Bcl-2 protein expression and long term survival in breast cancer. Am J Pathol 1994, 145(5), 1191-1198.
25. Bhargava V, Kell DL, Rijn M van de, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994, 145(3), 535-540.
26. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M, Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995, 60(1), 54-60.
27. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein Bcl-2 is expressed in well differentiated breast carcinomas with favourable prognosis. J Pathol 1995, 177(1), 49-55.
28. Gee JM, Robertson JF, Ellis IO, et al. Immunocytochemical localization of Bcl-2 protein in breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994, 59, 619-628.
29. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994, 69(1), 135-139.
30. Gorczyca W, Markiewski M, Kram A, Tuziak T, Domagala W. Immunohistochemical analysis of Bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virch Arch 1995, 426(3), 229-233.
31. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph-negative breast cancer patients. J Natl Cancer Inst 1994, 86(7), 499-504.
32. Hurlimann J, Larrinaga B, Vala DL. Bcl-2 protein in invasive ductal breast carcinomas. Virch Arch 1995, 426(2), 163-168.
33. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992, 80, 879-886.
34. Nathan B, Anbazhagan R, Clarkson P, Gusterson B. Expression of Bcl-2 in the developing human fetal and infant breast. Histopathology 1994, 80, 879-886.
35. Krazewski S, Chatten J, Hanada M, Reed JC. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparison with tumor cell differentiation and N-myc protein. Lab Invest 1995, 71, 42-54.
36. Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 1994, 73, 1673-1677.
37. Paraf F, Gogusev J, Chretien Y, Droz D. Expression of Bcl-2 oncoprotein in renal cell tumors. J Pathol 1995, 177, 247-252.
38. Pezzella F, Morrison H, Jones M, et al. Immunohistochemical detection of P53 and Bcl-2 protein in non-Hodgkin's lymphoma. Histopathology 1993, 22, 39-44.
39. Noguchi S, Aihara T, Koyama H, Motomura K, Inaji H, Imaoka S. Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer 1994, 74, 872-877.
40. Gump FE. Multicentricity in early breast cancer. Semin Surg Oncol 1992, 8, 117-121.
41. Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant Bcl-2 protein expression in gastric epithelial dysplasia. Cancer 1994, 73, 2900-2904.
42. Domagala W, Hazezga B, Szadowska A, Markiewski G, Weber K, Osborn M. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol 1993, 142, 669-674.
43. Ramani P, Lu Q-L. Expression of Bcl-2 gene product in neuroblastoma. J Pathol 1994, 172, 273-278.
44. Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the Bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukaemia cell lines. Ann Oncol 1994, 5, 61-65.
45. Brown R. Gene amplification and drug resistance. J Pathol 1991, 163, 287-292.
46. Leoncini L, Vecchio MT, Mega T, et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 1993, 142, 755-763.